NovaResp Technologies Enhances Sleep Apnea Therapy with AI
NovaResp Technologies, a Halifax-based medtech startup, is pioneering a new approach to sleep apnea therapy by integrating artificial intelligence with CPAP devices. Founded by Hamad Hanafi, NovaResp aims to improve the experience for patients suffering from obstructive sleep apnea, a condition that can lead to severe health issues like heart attacks and strokes. The company’s AI-driven algorithm predicts apnea events before they occur, allowing the device to intervene gently, thus enhancing patient comfort and adherence to therapy.
### Innovating Sleep Apnea Treatment
Hanafi, who holds a PhD in biomedical engineering, was inspired to innovate in this space after his father was diagnosed with severe sleep apnea. Traditional CPAP machines react to breathing disruptions after they happen, often waking patients with abrupt pressure changes. NovaResp’s technology, however, anticipates these events, reducing the need for sudden adjustments and making the therapy more tolerable.
NovaResp started in 2017, initially focusing on both hardware and software. The company has since honed its expertise in algorithm development, offering its software to CPAP manufacturers. This strategic pivot allows NovaResp to leverage its strengths and quickly bring its innovations to market.
### Building a Talent Pipeline
To support its growth, NovaResp has tapped into the Information and Communications Technology Council’s (ICTC) Work Integrated Learning (WIL) Digital program. This initiative provides wage subsidies to employers, enabling NovaResp to engage 34 student placements since 2021. The program not only offers financial support but also serves as a critical talent pipeline, allowing the company to retain skilled interns part-time as they continue their studies. This approach has led to five interns transitioning into full-time roles post-graduation, strengthening NovaResp’s workforce with individuals well-versed in the company’s culture and products.
### Future Prospects
Having completed two clinical trials, NovaResp is now exploring partnerships with CPAP machine manufacturers interested in its software. The company’s innovative approach could significantly impact the market by improving therapy adherence and outcomes for the estimated one billion people affected by sleep apnea worldwide. As NovaResp continues to refine its technology, it stands poised to make a substantial contribution to the medtech landscape, potentially setting a new standard for sleep apnea treatment.
